The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | NICE osimertinib rejection: UK patients

Name: NICE osimertinib rejection: UK patients
Uploaded: 2020-01-31T00:00:00Z
Duration: 1 min 8 s
Description: Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, talks on the rejection of osimertinib by NICE and the impact this may have on UK treatment outcomes, specifically patients with EGFR-mutant non-small cell lung cancer (NSCLC). This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Tom Newsom-Davis • 31 Jan 2020

BTOG 2020

Lung Cancer Non-Small Cell Lung Cancer Osimertinib

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, talks on the rejection of osimertinib by NICE and the impact this may have on UK treatment outcomes, specifically patients with EGFR-mutant non-small cell lung cancer (NSCLC). This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.